Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus

Abstract

Serum concentrations of three angiogenic cytokines: vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-18 (IL-18) and antiangiogenic factor endostatin in the serum of 52 patients with systemic lupus erythematosus (SLE) and 20 healthy subjects were investigated. The possible association between serum levels of these proteins and SLE activity as well as correlation between the concentrations of angiogenic cytokines and the level of endostatin was also analyzed. VEGF and IL-18 were detectable in all SLE patients and healthy control group. bFGF was measurable in 71.2% of patients with SLE and 65% of healthy persons. Endostatin was detectable in 94.2% of SLE patients and 95% of normal subjects. The serum levels of endostatin and bFGF were not significantly different in SLE and healthy control (P > 0.05). The median concentration of VEGF was higher in active SLE (238.4pg/ml) than in inactive disease (118.1pg/ml, P < 0.05) or in control group (133.5pg/ml, P < 0.04). The median serum level of IL-18 was higher in the SLE patients (595.2pg/ml) than in the control group (252.7pg/ml) (P < 0.001). The correlations between the levels of angiogenic cytokines and endostatin with clinical features, laboratory abnormalities and also with the type of treatment were analysed. We found a positive correlation between VEGF serum concentration and SLE activity according to SLAM score (r=0.275, P < 0.05). The significant positive correlation was also found between IL-18 and endostatin (r=0.289, P < 0.04). In contrast, the correlation between bFGF and endostatin was significantly negative (r=7 0.299, P < 0.04). In conclusion, serum levels of the angiogenic and antiangiogenic factors may play an important role in SLE pathogenesis.

Keywords

angiogenesis basic fibroblast growth factor disease activity endostatin IL-18 SLE vascular endothelial growth factor

Get full access to this article

View all access options for this article.

References

Folkman J . Clinical applications of research on angiogenesis . New Engl J Med 1995; 333: 1757–1763 .

Toi M , Taniguchi T , Yamamoto Y et al. Clinical significance of the determination of angiogenic factors . Eur J Cancer 1996; 32: 2513–2519 .

Auerbach W , Auerbach R . Angiogenesis inhibition: a review . Pharmacol Therapeut 1994; 63: 265–311 .

Dvorak HF , Detmar M , Claffey KP et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation . Int Arch Allergy Immunol 1995; 107: 233–235 .

Pepper MS . Manipulating angiogenesis. From basic science to the bedside . Artherioscl Throm Vas Biol 1997; 17: 605–619 .

Park CC , Morel JC , Amin MA et al. Evidence of IL-18 as a novel angiogenic mediator . J Immunol 2001; 167: 1644–1653 .

Kim Lee Sim B . Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth . Angiogenesis 1998; 2: 37–48 .

O'Reilly MS , Boehm T , Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth . Cell 1997; 88: 277–285 .

Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease . Nature Med 1995; 1: 27–31 .

10.

Talks KL , Harris AL . Current status of antiangiogenic factors . Br J Haematol 2000; 109: 477–489 .

11.

Kadono T , Kikuchi K , Kubo M et al. Serum concentrations of basicfibroblast growth factor in collagen diseases . J Am Acad Dermatol 1996; 35: 392–397 .

12.

Harada M , Mitsuyama K , Yoshida H et al. Vascular endothelial growth factor in patients with rheumatoid arthritis . Scand J Rheumatol 1998; 27: 377–380

13.

Robak E , Wozniacka A , Sysa-Jedrzejowska A et al. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity . Eur Cytokine Netw 2001; 12: 445–452 .

14.

Wong CK , Ho CY , Li EK , Lam CW . Elevation of proinflamatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus . Lupus 2000; 9: 589–593 .

15.

Wong CK , Li EK , Ho CY , Lam CW . Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus . Rheumatology 2000; 39: 1078–1081 .

16.

Hebbar M , Peyrat JP , Hornez L et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis . Arthritis Rheum 2000; 43: 889–893 .

17.

Nagashima M , Asano G , Yoshino S . Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis . J Rheumatol 2000; 27: 2339–2342 .

18.

Tan EM , Cohen AS , Fries JE et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982, 25: 1271–1277 .

19.

Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107–1118 .

20.

Robak E , Sysa-Jedrzejowska A , Stepien H , Robak T . Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus . Eur Cytokine Netw 1997; 8: 281–286 .

21.

Schar PH . Clinical features of SLE. In: Kelly WN , Harris ED , Puddy S , Sledge CB (eds). Textbook of Rheumatology, 4th edn. WB Saunders: Philadelphia, PA , 1993, p 1017-1017.

22.

Stephansson EA , Niemi KM , Jouhikainen T et al. Lupus anticoagulant and the skin. A long term follow-up study of SLE patients with special reference to histopathological findings . Acta Derm Venereol 1991; 71: 416–422 .

23.

Dinarello CA . IL-18: a Th1—inducing, proinflammatory cytokine and new member of the IL-1 family . J Allergy Clin Immun 1999; 103: 11–24 .

24.

Coughlin CM , Salhany KE , Wysocka M et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis . J Clin Invest 1998; 101: 1441–1452 .

25.

Cao R , Farnebo J , Kurimoto M , Cao Y . Interleukin-18 acts as an angiogenesis and tumor suppressor . FASEB J 1999; 13: 2195–2202 .

26.

Feldman AL , Tamarkin L , Paciotti GF et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer . Clin Cancer Res 2000; 6: 4628–4634 .

27.

Feldman AL , Pak H , Yang JC et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma . Cancer 2001; 91: 1525–1529 .

28.

Yammamoto T , Katayama I , Nishioka K . Involvement of basicfibroblast growth factor in fibroblast—stimulatory serum activity of a patient with systemic lupus erythematosus and multiple dermatofibromas . Dermatology 1995; 91: 281–285 .

29.

Dinarello CA , Novick D , Puren AJ et al. Overview of interleukin-18: more than an interferon-g-induced factor . J Leukocyte Biol 1998; 63: 658–664 .

30.

Dinarello CA . Role of pro and anti-inflammatory cytokines during inflammation: experimental and clinical findings . J Biol Reg Homeos Agents 1997; 11: 91–103 .

31.

Yamamoto Y , Tor M , Kondo S et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients . Clin Cancer Res 1996; 2: 821–826 .

32.

Feldman AL , Restifo NP , Alexander HR et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice Cancer Res 2000; 60: 1503–1506 .

33.

Lamoreaux WJ , Fitzgerald MEC , Reiner A et al. Vascular endothelial growth factor increase release of gelatinase A and decrease release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro . Microvasc Res 1998; 55: 29–42 .

34.

Umori EN , Ferrara N , Baner EA , Amento EP . Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells . J Cell Physiol 1992; 153: 557–562 .

35.

Zucker S , Mirza H , Cenner CE et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation . Int J Cancer 1998; 75: 780–786 .

36.

Halfer W , Dong S , Schurer B , Cole GL . Collagen XVIII is a basement membrane heparan sulfate proteoglycan . J Biol Chem 1998; 25: 25404–25412 .

37.

Calderon P , Anzilotti M , Phelps R . Thalidomide in dermatology. New indications for an old drug . Int J Dermatol 1997; 36: 881–887 .

38.

Walchner M , Meurer M , Plewig G , Messer G . Clinical and immunological parameters during thalidomide treatment of lupus erythematosus . Int J Dermatol 2000; 39: 383–388 .